# W. Lowry Caudill

> W. Lowry Caudill is a Series A investor at Southern Capitol Ventures backing Biopharma. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Southern Capitol Ventures](https://shizune.co/investors/profile/southern-capitol-ventures)
- Location: Durham, United States
- Total investments: 1
- Last investment: Jun 2006
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/lowry-caudill-801a3131

W. Lowry Caudill is a Series A investor at Southern Capitol Ventures in Durham focused on Biopharma and Therapeutics. Lowry Caudill is the retired, worldwide President of Pharmaceutical Development for Cardinal Health. The Pharmaceutical Development business unit provided complete development services for the pharmaceutical industry. Caudill led over 1400 employees in nine sites including RTP, San Diego, Somerset NJ, Philadelphia, Manchester UK and Schorndorf GER.In April 2002, Cardinal Health acquired Magellan Laboratories Incorporated, a pharmaceutical development company that Caudill and Alfred Childers co-founded in 1991. Under their leadership Magellan grew to 600 people with 500 employees in RTP and 100 employees in San Diego. Magellan was recognized as one of the fastest growing, privately held companies in the Research Triangle area and received numerous regional and national awards for growth and entrepreneurial development. Magellan was awarded the Triangle Business Journal’s Fast 50 award for nine years and was in the Top 10 for six of the nine years. In 1998, Drs. Caudill and Childers were named Entrepreneur of the Year for North and South Carolina by Ernst and Young, the Kauffman Foundation, USA TODAY, and NASDAQ and were Finalists for the 1998 National Entrepreneur Of The Year. They received two awards from the North Carolina Council for Entrepreneurial Development (CED), the 2002 Entrepreneurial Excellence Award and the 2002 Deal of the Year Award.Caudill received his B.S. degree in Chemistry at the University of North Carolina at Chapel Hill with undergraduate research under the direction of Professor Royce Murray. In 1983, Caudill received his doctorate in Analytical Chemistry from Indiana University under the direction of Professor R. Mark Wightman. His dissertation was titled Development and Application of High Performance Liquid Chromatography with Electrochemical Detection. Upon graduation, he became a research scientist at Baxter-Travenol. In addition to general fanatical activities, he managed a formulation development laboratory, which was responsible for the formulation, development and stability evaluation of frozen premixed parenteral products. In 1987, he joined the Glaxo Research Institute where he played a major role in the establishment of the Analytical Chemistry Department in RTP. Currently marketed product lines which his groups helped develop include Zantac, Imitrex, Zofran, Zinacef, and Ventolin.Caudill is an active entrepreneur and supporter of entrepreneurial endeavors. He serves on the Advisory Board of Southern Capitol Ventures, serves on the Life Sciences Advisory Board of the Aurora Funds and is a member of the Tri-State Investment Group. He is an investor in and member of the Board of Directors of Liquidia Technologies Incorporated. He is a former board member of and investor in Knowledge Vector, Piedmont Pharmaceuticals and Aldagen Inc.Caudill is Chair of the Board of Trustees at the University of North Carolina at Chapel Hill and of the University’s Innovation Circle. He was a Steering Committee member of the $2.4 billion Carolina First Campaign and is chair of the Private Fundraising Steering Committee for the UNC-CH Physical Science Complex. He is an Adjunct Professor of Chemistry at the UNC-CH and a member of the UNC-CH Chemistry Department External Advisory Board. He is a member of the Advisory Working Group for the UNC-CH Entrepreneurship Minor and is chair of the Private Fundraising Campaign for the Entrepreneurship Minor. He and Professor Holden Thorp created and taught the first Scientific Ventures course for the UNC-CH Entrepreneurship Minor. In the spring semesters of 2008 and 2009, he co-taught the Scientific Ventures course with Professor Joe DeSimone. He co-taught the Introduction to Entrepreneurship course in 2007 and 2008 for the Entrepreneurship Minor. He is a member of the Executive Board of The Educational Foundation at UNC-CH. In 2008, he received the Distinguished Alumnus Award from UNC-CH.He is an active member of the American Chemical Society (ACS) and the American Association of Pharmaceutical Scientists (AAPS).Dr. Caudill has chaired numerous boards at Aldersgate United Methodist Church in Durham, NC and presently serves as chair of the Administrative Board and the Building Committee. He was a Team Leader for the Aldersgate 2008 Jamaica Mission Team. Dr. Caudill, and his wife, Suzi, and children reside in Durham. His oldest daughter is a senior at UNC-CH and his son is a sophomore at UNC-CH.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 100% |
| Therapeutics | 1 | 100% |
| Biotechnology | 1 | 100% |
| Nanotechnology | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Liquidia Technologies | Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed toimprove the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration. | $6M | Series A | Jun 14, 2006 |  |

1 of 1 investments shown.

## Co-investors
- [Firelake Capital Management](https://shizune.co/investors/profile/firelake-capital-management) — VC Fund, 1 deal together
- [Siemens](https://shizune.co/investors/profile/siemens) — VC Fund, 1 deal together
- [Wakefield Group](https://shizune.co/investors/profile/wakefield-group) — VC Fund, 1 deal together

## About Southern Capitol Ventures

VC Fund · Raleigh, United States

Southern Capitol Ventures is a venture capital firm specializing in early-stage and mid stage companies. The firm also considers investing in later stage opportunities and spinouts partnering with larger venture capital funds. It considers investments in technology and life science businesses, which typically includes e-commerce, software, digitalmedia, wireless, mobile, and healthcare information technology.

5 contacts available at Southern Capitol Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| W. Lowry Caudill | Board Member | https://shizune.co/investors/profile/w-lowry-caudill |
| Ben Brooks | Founding Partner | https://shizune.co/investors/profile/ben-brooks |
| Cindy Kasner | Administrative Operations | https://shizune.co/investors/profile/cindy-kasner |
| David Jones | Partner | https://shizune.co/investors/profile/david-jones-3 |
| David S. Jones | Partner | https://shizune.co/investors/profile/david-s-jones |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does W. Lowry Caudill invest in?

W. Lowry Caudill invests primarily in Biopharma, Therapeutics and Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did W. Lowry Caudill last invest?

The most recent investment recorded for W. Lowry Caudill closed in Jun 2006. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co